Brokerages Set Ultragenyx Pharmaceutical Inc. (NASDAQ:RARE) Price Target at $88.92

Ultragenyx Pharmaceutical Inc. (NASDAQ:RARE) has earned an average rating of “Hold” from the eighteen brokerages that are covering the stock, MarketBeat Ratings reports. One equities research analyst has rated the stock with a sell recommendation, nine have given a hold recommendation and eight have given a buy recommendation to the company. The average 1 year price objective among brokers that have updated their coverage on the stock in the last year is $89.17.

RARE has been the topic of several analyst reports. Zacks Investment Research raised Ultragenyx Pharmaceutical from a “sell” rating to a “hold” rating in a research report on Tuesday, July 18th. SunTrust Banks, Inc. increased their target price on Ultragenyx Pharmaceutical from $100.00 to $105.00 and gave the stock a “buy” rating in a research report on Wednesday, April 19th. Robert W. Baird reaffirmed an “outperform” rating and issued a $90.00 target price on shares of Ultragenyx Pharmaceutical in a research report on Wednesday, April 19th. Canaccord Genuity set a $98.00 target price on Ultragenyx Pharmaceutical and gave the stock a “buy” rating in a research report on Friday, July 28th. Finally, BidaskClub lowered Ultragenyx Pharmaceutical from a “buy” rating to a “hold” rating in a research report on Tuesday, August 1st.

ILLEGAL ACTIVITY WARNING: This piece of content was reported by BNB Daily and is the property of of BNB Daily. If you are accessing this piece of content on another site, it was illegally stolen and republished in violation of US and international copyright & trademark legislation. The legal version of this piece of content can be viewed at https://www.baseball-news-blog.com/2017/08/19/brokerages-set-ultragenyx-pharmaceutical-inc-nasdaqrare-price-target-at-88-92-updated.html.

In related news, VP Theodore Alan Huizenga sold 480 shares of the stock in a transaction on Friday, May 26th. The stock was sold at an average price of $57.46, for a total value of $27,580.80. Following the completion of the transaction, the vice president now owns 9,366 shares in the company, valued at approximately $538,170.36. The transaction was disclosed in a filing with the Securities & Exchange Commission, which is available at the SEC website. Company insiders own 9.20% of the company’s stock.

Large investors have recently made changes to their positions in the company. Aureus Asset Management LLC raised its stake in Ultragenyx Pharmaceutical by 935.5% in the first quarter. Aureus Asset Management LLC now owns 50,740 shares of the biopharmaceutical company’s stock worth $2,927,000 after buying an additional 45,840 shares during the period. Swiss National Bank raised its stake in Ultragenyx Pharmaceutical by 3.9% in the first quarter. Swiss National Bank now owns 63,952 shares of the biopharmaceutical company’s stock worth $4,335,000 after buying an additional 2,400 shares during the period. Columbia Wanger Asset Management LLC raised its stake in Ultragenyx Pharmaceutical by 5.3% in the first quarter. Columbia Wanger Asset Management LLC now owns 1,237,825 shares of the biopharmaceutical company’s stock worth $83,900,000 after buying an additional 62,209 shares during the period. FMR LLC raised its stake in Ultragenyx Pharmaceutical by 3.9% in the first quarter. FMR LLC now owns 6,110,627 shares of the biopharmaceutical company’s stock worth $414,178,000 after buying an additional 227,802 shares during the period. Finally, Mutual of America Capital Management LLC raised its stake in Ultragenyx Pharmaceutical by 14.4% in the first quarter. Mutual of America Capital Management LLC now owns 38,320 shares of the biopharmaceutical company’s stock worth $2,597,000 after buying an additional 4,837 shares during the period. 95.40% of the stock is owned by hedge funds and other institutional investors.

Shares of Ultragenyx Pharmaceutical (RARE) traded up 0.11% during trading on Friday, hitting $64.14. 203,982 shares of the stock were exchanged. The stock’s market cap is $2.72 billion. Ultragenyx Pharmaceutical has a one year low of $51.67 and a one year high of $91.35. The stock’s 50 day moving average price is $65.29 and its 200 day moving average price is $67.43.

Ultragenyx Pharmaceutical (NASDAQ:RARE) last posted its quarterly earnings results on Thursday, July 27th. The biopharmaceutical company reported ($1.72) earnings per share (EPS) for the quarter, beating the Thomson Reuters’ consensus estimate of ($1.73) by $0.01. During the same period last year, the business earned ($1.46) EPS. Equities research analysts predict that Ultragenyx Pharmaceutical will post ($7.23) EPS for the current year.

Ultragenyx Pharmaceutical Company Profile

Ultragenyx Pharmaceutical Inc is a clinical-stage biopharmaceutical company. The Company is focused on the identification, acquisition, development, and commercialization of products for the treatment of genetic diseases. Its clinical-stage pipeline consists of two product categories: biologics (including a monoclonal antibody and an enzyme replacement therapy), and small-molecule substrate replacement therapies.

Analyst Recommendations for Ultragenyx Pharmaceutical (NASDAQ:RARE)

Receive News & Ratings for Ultragenyx Pharmaceutical Inc. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Ultragenyx Pharmaceutical Inc. and related companies with MarketBeat.com's FREE daily email newsletter.

Latest News

Leave a Reply